(Q28304273)
Statements
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors (English)
0 references
15 March 2011
0 references
17
0 references
6
0 references
1561-70
0 references
2 references
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference